Caribou Biosciences (CRBU)

• Market cap: $187M
• 1 day: -1.53%
• 5 days: -1.03%
• 1 month: -4.93%
• 3 months: 22.15%
• 6 months: -22.49%
• Year to date: 21.38%
• 1 year: 124.55%
• 5 years: -88.17%
• 10 years: -88.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Employees: 97